|
Market Closed -
Nasdaq
16:00:00 2025-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 5.670 USD | -.--% |
|
-.--% | - |
| 25-10-07 | MannKind Corporation completed the acquisition of scPharmaceuticals Inc.. | CI |
| 25-10-07 | MannKind Completes Acquisition of scPharmaceuticals | MT |
| Market Cap | 305M 263M 248M 226M 422M 29.09B 426M 2.95B 1.14B 14.81B 1.14B 1.12B 47.07B | P/E 2023 |
-4.41x | P/E 2024 | -1.85x |
|---|---|---|---|---|---|
| Enterprise Value | 281M 242M 228M 208M 389M 26.8B 392M 2.72B 1.05B 13.64B 1.05B 1.03B 43.37B | EV / Sales 2023 |
13,839,720x | EV / Sales 2024 | 4,215,542x |
| Free-Float |
98.42% | Yield 2023 * |
-
| Yield 2024 | - |
Last Transcript : scPharmaceuticals Inc.
| 1 year | 5.61 |  | 5.7 |
| 3 years | 1.94 | | 7.7 |
| 5 years | 1.94 | | 12.75 |
| 10 years | 1.94 | | 18.17 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 49 | 2025-10-06 |
| Director of Finance/CFO | 50 | 2025-10-06 | |
David Thomson
SEC | Corporate Secretary | 59 | 2025-10-06 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Castagna
BRD | Director/Board Member | 49 | 2025-10-06 |
David Thomson
BRD | Director/Board Member | 59 | 2025-10-06 |
| Director/Board Member | 50 | 2025-10-06 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/7/25 | Issuer sale | Director | 72,174 | 0.1442% | ||
| 10/7/25 | Issuer sale | Director | 84,422 | 0.1687% | ||
| 10/7/25 | Issuer sale | Director | 49,750 | 0.0994% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | +0.89% | -23.48% | 305M | |
| -0.11% | -3.20% | +49.61% | +91.49% | 1,002B | |
| -0.27% | -3.22% | +50.51% | +65.89% | 644B | |
| +1.63% | -2.57% | +21.19% | +71.12% | 443B | |
| -0.63% | -1.06% | +28.11% | +34.59% | 343B | |
| +0.43% | -14.61% | +9.88% | +27.26% | 262B | |
| +0.93% | -1.82% | -1.82% | +8.41% | 245B | |
| -2.25% | -13.63% | +36.61% | +47.43% | 212B | |
| -0.90% | -5.09% | -15.47% | -57.75% | 199B | |
| -0.58% | -3.21% | +25.10% | +90.54% | 181B | |
| Average | +0.20% | -4.50% | +20.46% | +35.55% | 353B | |
| Weighted average by Cap. | +0.43% | -4.24% | +31.90% | +57.11% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 13.59 11.71 11.05 10.06 18.81 1.3K 18.99 131.64 50.63 660.2 51.04 49.92 2.1K | 36.33 31.3 29.54 26.89 50.27 3.47K 50.76 351.85 135.34 1.76K 136.43 133.43 5.61K |
| Net income | -54.81M -47.21M -44.57M -40.57M -75.84M -5.23B -76.57M -531M -204M -2.66B -206M -201M -8.46B | -85.15M -73.35M -69.24M -63.03M -118M -8.13B -119M -825M -317M -4.14B -320M -313M -13.15B |
| Net Debt | -36.72M -31.63M -29.86M -27.18M -50.81M -3.5B -51.3M -356M -137M -1.78B -138M -135M -5.67B | -23.98M -20.66M -19.5M -17.75M -33.18M -2.29B -33.51M -232M -89.34M -1.16B -90.06M -88.08M -3.7B |
Employees
163
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SCPH Stock
Select your edition
All financial news and data tailored to specific country editions
